Clinical Options and Challenges in Ph+ Leukemia

Transcription

Satellite Symposium at the
18th Congress of European Hematology
Association (EHA)
Clinical Options
and Challenges in
Ph+ Leukemia
Following Resistance
or Intolerance to Initial
Lines of Tyrosine Kinase
Inhibitors
13 June 2013 • 08:00 -10:00
Hall A9 • Stockholmsmässan, Sweden
Clinical Options and Challenges in Ph+ Leukemia
Following Resistance or Intolerance to Initial Lines of Tyrosine
Kinase Inhibitors
13 June 2013 • 08:00-10:00
08:00-08:10
Introduction and CML case study
Professor Michele Baccarani (Chair)
Universitá di Bologna
Bologna, Italy
Current clinical options and challenges after resistance/intolerance to
first-/second-generation TKIs in Ph+ CML
Professor Francois Guilhot
Centre Hospitalier Universitaire, La Miletrie
Poitiers, France
first-/second-generation TKIs in Ph+ ALL
Professor Oliver G. Ottmann
Medizinische Klinik II, Johann Wolfgang Goethe Universität
Frankfurt am Main, Germany
How will we manage CML in the next 5 years?
Professor Stephen G. O’Brien
Northern Institute for Cancer Research, Newcastle University Medical School
Newcastle upon Tyne, United Kingdom
Discussion
Moderator: Professor Michele Baccarani
Closing remarks
Professor Michele Baccarani
08:10-08:35
08:35-09:00
09:00-09:25
09:25-09:55
09:55-10:00
Symposium Location: Hall A9
M11
16P
M10
20P
M13
28P
M12
20P
M15
20P
M14
8P
M16
28P
M18
8P
M17
20P
M19
28P
M20
16P
S ERVICECE NTER
B AC K OFFICE
B USIN ESSC ENTER
1 2 DA
COMP
TAPL
UTERS
ATSER
B TORE
S
UTIK
Höjd 3.5
90p
Höjd 5.0
TEKNIKER
K17
K16
Vt
Vt
15x5x0.8
WC
Vt
A1
3010p
Höjd 7.60
Höjd 7.60
Vt
AP1,2
Vt
Höjd 2.8
K1/K2
860p
Höjd 2.3
Vt
A2/A3
1010p
AP3,1
AP2,1
AP1,1
K5
TEKN
GARDEROB
KONGRESSEN
K4
RESTAURANT
KLUBBEN
WC
WC
AP4,1
A4/A5
AP5,1
Hall
A2/A3
3F 32A
Vt
Vt
Vt
Vt
Vt
Hall
A4/A5
Vt
A6
AP7,1
12x3x0.6
430p
3F 16A
Vt
12x3x0.8
Vt
AP6,1
804p
3F 16A
Vt
Vt
Höjd 7.60
WC
70p
AP9,2
AP8,2
AP10,2
AP11,2
AP10,1
AP11,1
Höjd 9.60
.
A7
AP8,1
12x3x0.6
430p
A8
AP9,1
12x3x0.6
Hall
A7
3F 32A
Vt
Vt
Vt
12x3x0.6
Hall
A9
Hall
A8
Höjd 7.60
WC
TEKN
A9
50p
430p
12x3x0.8
Vt
TEKN
TEKN
TEKN
5x3x 0.4
K3
Höjd 2.9
Höjd 2.9
H ISS
SAMARIT
K6
K7
GARDEROB 5
PRESSBYRÅN
PÄLSGARDEROBEN
WC
WC
WC
WC
RESTAURANT NIGIRI SUSHI 132p
RESTAURANT CAFFÈ GALLERIA 132p
WC
WC
WC
WC
STENRUM
LOUNGE
VIP
Höjd 6,0
Höjd 3,2
Höjd 5,3
1,5m Fritt
E l skåp
E l skåp
E l skåp
E l skåp
E l skåp
E l skåp
1,5m Fritt
1,5m Fritt
1,5m Fritt
BP12,1
BP12,2
Ö
BP10,2
,
1,5m Fritt
GARDEROB 1b
BP11,1
BP11,2
,
ENTRÉHALL
Höjd 6.15
B10
BP8,1
BP7,1
BP6,1
BP5,1
BP4,1
BP3,2
BP2,1
6x3x 0.4
120p
Höjd 7.0
5x19x1
BP12,3
Höjd 5,0
WC
Registration
Höjd 5.11
Höjd 8.60
B3
Hospitality Areas
Höjd 6,0
INFO
GARDEROB 1a
Victoria Hall
BP11,3
BP10,3
,3
BP9,2
BP3,3
LOGE
G
BP9,1
WC
BP1,1
ARTIST
LOUNGE
EHA
Booth
BANK
BP3,1
LOGE
GP2,1
Höjd 5,3
BP10,1
LOGE
GP2,2
GP1,1
Höjd 5.11
BANKOMAT
P ENTRY
GP1,2
GARDEROB
PLOGEN
RESTAURANT BURGER SHOP 240p
K ONSTVERK
1,5m Fritt
K12
AP7,2
AP6,2
Höjd 9.60
Höjd 15.5
.
.
AP5,2
AP4,2
AP3,2
AP2,2
Vt
Hall
A1
45p
.
Vt
Vt
Höjd 2.5
K13
Hall
K1/K2
E l skåp
45p
1,5m Fritt
45p
K14
TEKN
K15
BP10,4
BP11,4
BP12,4
BP10,5
BP11,5
BP12,5
BP9,3
TEKN
TEKN
BP8,2
BP7,2
BP6,2
BP5,2
BP3,5
BP4,2
BP2,2
BP1,2
E l skåp
1,5m Fritt
E l skåp
1,5m Fritt
E l skåp
1,5m Fritt
E l skåp
1,5m Fritt
E l skåp
1,5m Fritt
E l skåp
E l skåp
1,5m Fritt
1,5m Fritt
RESTAURANT
FLAVOUR BAR
30p
.
70p
BP3,4
SL CENTER
BP9,4
BP3,6
BP10,6
PV1
h=2200
B8
BP10,7
BP12,6
BP11,6
B7
6x3x 0.4
100p
6x3x 0.4
100p
BP12,7
BP11,7
PV2
h=6600
VÄ
300P
ST
RA
ENT
RÉN
RESTAURANT
FLAVOUR KITCHEN
268p
BP
BP
BP
Main Entrance
RESTAURANT
THE GARDEN
220p
VERKSTAD
LADDRUM
G
TOMGODS
WC
WC
GARDEROB
HALL C
TOMGODS
SERVICE
CENTER C
.
,
,
,
,
,
,
,
,
,
,
,
,
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
,
.
SATELLITE SYMPOSIA BOOKLET
THURSDAY JUNE 13, 2013
18th CONGRESS
of the
European Hematology Association
STOCKHOLMSMÄSSAN
SWEDEN
JUNE 13 – 16
2013
Download the
EHA18 - App to your
smartphone
and tablet
The App includes
the Satellite
Symposia Programs
European Hematology Association
@EHA_Hematology
TABLE OF CONTENTS
Words of Welcome
4
EHA Board and Organization 18th Congress
5
Program-at-a-Glance
6
Floor plan Stockholmsmässan
7
Satellite Symposia Programs
10
Acknowledgements
36
ehaweb.org
3
EHA BOARD & ORGANIZATION
18 t h CONGRESS
EHA EXECUTIVE BOARD
U Jäger, President, Austria
C Chomienne, France
R Foà, Italy
J Sierra, Spain
A Green, United Kingdom
EHA BOARD
A Borkhardt, Germany
D Bron, Belgium
A Brand, the Netherlands
J Cools, Belgium
A Engert, Germany
A Falanga, Italy
D Grimwade, United Kingdom
L Malcovati, Italy
G Ossenkoppele, the Netherlands
P Sonneveld, the Netherlands
SCIENTIFIC PROGRAM COMMITTEE
18th CONGRESS
J Sierra, Spain (Chair)
A Green, United Kingdom
C Camaschella, Italy
P Hillmen, United Kingdom
S Izraeli, Israel
F Leebeek, the Netherlands
M Manz, Switzerland
H Serve, Germany
A Falanga, Italy
C Montalban, Spain
G Socié, France
LOCAL REPRESENTATIVE
18th CONGRESS
E Hellström-Lindberg, Sweden
4
SCIENTIFIC PROGRAM COMMITTEE
ADVISORY BOARD 18th CONGRESS
E Angelucci, Italy
I Bodo, Hungary
A Brand, the Netherlands
R Delwel, the Netherlands
H Dombret, France
B Falini, Italy
R Hajek, Czech Republic
A Hochhaus, Germany
H Johnsen, Denmark
S Karlsson, Sweden
C Klein, Germany
P Ljungman, Sweden
L Macintyre, France
M Mateos, Spain
H Pahl, Germany
D Perry, United Kingdom
G Saglio, Italy
E Solary, France
K Stamatopoulos, Greece
S Stilgenbauer, Germany
J Storry, Sweden
A Sureda, Spain
A Taher, Lebanon
P Valk, the Netherlands
CORPORATE SPONSOR COMMITTEE
A Falanga, Italy (Chair)
G Saglio, Italy
R Foà, Italy
EHA Executive Office
Koninginnegracht 12b
2514 AA The Hague
The Netherlands
Tel: +31 (0)70 3455 563
Fax: +31 (0)70 3923 663
E-mail: info@ehaweb.org
Website: www.ehaweb.org
WORDS OF WELCOME
On behalf of the European Hematology Association (EHA) we are pleased to
invite you to attend the 18th Congress of EHA in Stockholm June 13-16, 2013.
The EHA Congress has become the most important meeting for laboratory
and clinical hematologists organized in Europe. It attracts a growing number
of participants from European and non-European countries and offers
important information on the latest results in basic and clinical research, as
well as state-of-the-art education sessions in diagnostics and therapeutics.
Oral presentations and poster sessions offer opportunities for investigators,
especially younger scientists, to present their work.
In this separate satellite symposia booklet you will find all 26 programs of
the Satellite Symposia which take place on Thursday, June 13. The
symposia highlight recent progress in diagnosis and therapeutic innovation
in both benign and malignant hematological disorders. All topics and
presentations have been approved by the Scientific Program Committee.
We hope that you will also attend many of the other activities EHA offers
during this year’s Congress and will have time to visit the pharmaceutical
industry exhibition.
We look forward to meeting you at the 18th Congress of EHA in Stockholm.
J Sierra
Chair Scientific Program Committee
Anna Falanga
Chair Sponsor Committee
ehaweb.org
5
PROGRAM-AT-A-GLANCE
Hall A1
Victoria Hall
Hall A2/A3
08:00
Hall A4/A5
Hall K1/K2
Astellas
Pharma
Europe Ltd:
Clearing the
hurdles: Practical
perspectives on
antimicrobial
selection
Page 10
10:00
10:45
prIME
Oncology:
Novartis
Oncology:
Relapsed/
Refractory
Multiple Myeloma:
Therapeutic
Opportunities for
Advanced Disease
Page 15
Sanofi:
GlaxoSmith
Kline
Oncology:
Bristol-Myers
Squibb:
Advances in the
management of
CML: From
frontline therapy
to treatment-free
remission
Selective
JAK/STAT
Inhibition:
Signalling a Way
Forward in the
Management of
Myelofibrosis
Beyond platelet
counts: extending
experience of
managing chronic
adult ITP
Page 16
Page 17
Page 18
Page 19
Novartis
Oncology:
Pfizer:
Janssen:
Celgene:
Next steps for
targeted therapy
in MPN
Latest
Developments
and Future
Strategies in Adult
Leukemias
Confessions of a
myeloma expert
Evolving
strategies to
manage MDS and
AML in the elderly
Page 22
Page 23
Page 24
Page 25
Personalized
Medicine towards
best Long term
outcomes in
CP-CML
12:45
13:30
15:30
16:15
F. Hoffmann-La
Roche Ltd:
Innovations in
antibody therapy
for lymphoid
malignancies
Page 29
18:15
6
GlaxoSmith
Kline
Oncology:
Novel strategies
for predicting
response to
treatment in
refractory CLL
Page 30
Celgene:
Current and future
therapeutic
strategies for
multiple myeloma
Page 31
JUNE 13, 2013
Hall T1/T2
Hall C6/C7
Millennium:
The Takeda
Oncology
Company:
Future
Therapeutic
Approaches
Targeting CD30 in
Haematological
Disorders
Page 11
Hall A7
Hall A8
Hall A9
Mundipharma:
Mundipharma:
Ariad:
Raising
expectations in
the unfit CLL
patient
Balancing the
efficacy and
toxicity of
therapeutic
approaches in
CNS disease in
aggressive
haematological
malignancies
Clinical Options
and Challenges in
Ph+ Leukemia
Following
Resistance or
Intolerance to Initial
Lines of Tyrosine
Kinase Inhibitors
Page 12
Page 13
Page 14
08:00
10:00
Celgene:
Mundipharma:
The role of novel
therapies in
improving
responses and
therapy duration
in CLL and NHL
Defining optimal
combination
strategies in the
management of
follicular and
mantle cell
lymphomas
Page 20
Page 21
10:45
12:45
13:30
Amgen:
Invivoscribe:
Teva:
Breaking barriers
with biologics:
examples in ITP
and ALL
The Evolution of
Clonality Testing –
Next Generation
Sequencing in the
Diagnosis and
Monitoring of
Hematologic
Malignancies
Raising the
standards in the
management of
haematology
patients
Page 26
Page 27
Page 28
15:30
Novartis
Oncology:
Where are we
today in the
management of
transfusion- and
non-transfusiondependent
thalassemia?
Page 32
Alexion:
Vifor Pharma:
Advances in the
management of
complementmediated
thrombotic microangiopathies
Master Class on
Iron Metabolism
and IV Iron
Page 33
Page 34
16:15
Genzyme,
a Sanofi
company:
The Sherlock
Holmes Approach
to Diagnosis and
Treatment: White
blood cell
changes in rare
haematological
diseases
Page 35
18:15
ehaweb.org
7
FLOOR PLAN STOCKHOLMSMÄSSAN
FIRST FLOOR
K16/
K17
EHA Offices
K11-K17
G
K15
K14
Hall
K1/K2
Hall A1
K13
K11
K4
K12
K3
9
Hall A2/A3
1
5
8
Victoria Hall
K24
EHA
Booth
2
Registr
7
Spe
Servic
K23
K22
K21
MAIN
ENTRANCE
C2
T6
C
6
a
l
Ric ote
H
k
l
a
T
T5
T4 T3
C
Hall T1/T2
8
C8
Hall
C6/C7
GROUND FLOOR
Hall A4/A5
Hall
A7
Hall A6
Press
Center
Rooms M10 - M20
Hall
A8
Hall
A9
(first floor)
B10
3
Hall B
EAST ENTRANCE
(BUS ENTRANCE)
B9
ation Area
Hospitality Areas
B3
eaker
ce Center
B8
1 CME Booth
C3
2 Podcast Room
3 Internet Corners
4 Poster Desk
Hall C
Exhibition, Posters & Catering Area
Rooms M50 - M54
C5
7
B7
3
3
5 Business Center
6 Early Career Club
7 First Aid and Security
4
8 Bank / Cash machine
9 Praying Rooms
ehaweb.org
9
SATELLITE SYMPOSIUM SUPPORTED BY ASTELLAS PHARMA EUROPE LTD.
08:00 – 10:00, Hall: A4/A5
CLEARING THE HURDLES: PRACTICAL PERSPECTIVES ON
ANTIMICROBIAL SELECTION
Chairperson: M Bergwelt-Baildon (Germany)
08:00 – 08:25
Welcome and Introduction
M Bergwelt-Baildon (Germany)
08:25 – 08:45
Facing the challenges of invasive fungal infections
C Cordonnier (France)
08:45 – 09:05
Overcoming obstacles to effective antifungal prophylaxis
09:05 – 09:25
Recognising the challenge we face in C. difficile infection
D Nathwani (United Kingdom)
09:25 – 09:45
Staying on the right track in the management of C. difficile infection
Catherine Cordonnier (France)
09:45 – 10:00
Panel discussion and Close
10
SATELLITE SYMPOSIUM SUPPORTED BY MILLENNIUM:
THE TAKEDA ONCOLOGY COMPANY
08:00 – 10:00, Hall: T1/T2
FUTURE THERAPEUTIC APPROACHES TARGETING CD30
IN HAEMATOLOGICAL DISORDERS
Chair: F D’Amore (Aarhus University Hospital, Aarhus, Denmark)
08:00 – 08:30
CD30: A diagnostic marker in haematological malignancies
S Pileri (Bologna University School of Medicine, Bologna, Italy)
08:30 – 09:00
CD30 and the molecular biology of Hodgkin lymphoma
R Küppers (University of Duisburg-Essen, Essen, Germany)
09:00 – 09:30
Targeting CD30 in Hodgkin lymphoma: changing therapeutic paradigms
P Borchmann (University of Cologne, Cologne, Germany)
09:30 – 10:00
CD30 and systemic anaplastic large cell lymphoma: an evolving story
F D’Amore (Aarhus University Hospital, Aarhus, Denmark)
ehaweb.org
11
SATELLITE SYMPOSIUM SUPPORTED BY MUNDIPHARMA INTERNATIONAL
08:00 – 10:00, Hall: C6/C7
RAISING EXPECTATIONS IN THE LESS FIT CLL PATIENT
Chair: C Wendtner (Städtische Klinikum München, Munich, Germany)
08:00 – 08:15
Welcome
C Wendtner (Städtische Klinikum München, Munich, Germany)
08:15 – 08:45
The challenge of the less fit CLL patient- what are the options today?
V Leblond (Hôpital Pitié-Salpêtrière, Paris, France)
08:45 – 09:05
Matching therapy to patient- would a new fitness score help?
V Goede (Uniklinik Köln, Cologne, Germany)
09:05 – 09:25
For whom is MRD negativity now a realistic goal?
P Ghia (Università Vita-Salute San Raffaele, Milan, Italy)
09:25 – 09:45
A look at the future of CLL treatment - New options and new outcomes
G Follows (Addenbrooke’s, Cambridge University Hospital NHS Trust, United
Kingdom)
09:45 – 10:00
Towards personalised therapy - key questions and the trials to answer
them
C Wendtner (Klinikum Schwabing, Munich, Germany)
12
08:00 – 10:00, Hall: A8
BALANCING THE EFFICACY AND TOXICITY OF THERAPEUTIC
APPROACHES IN MANAGING CNS DISEASE
Chairs: D Hoelzer (Frankfurt, Germany)
M Björkholm (Karolinska University Hospital, Stockholm, Sweden)
08:00 – 08:10
Opening: Central nervous system disease in haematological
malignancies
D Hoelzer (Frankfurt, Germany)
08:10 – 08:30
Management of older patients with acute lymphoblastic leukaemia
N Gökbuget (University Cancer Center Goethe University Hospital, Frankfurt,
Germany)
08:30 – 08:40
Questions
08:40 – 08:50
Central nervous system disase in aggresive nhl
M Björkholm (Karolinska University Hospital, Stockholm, Sweden)
08:50 – 09:10
MANAGMENT OF PRIMARY CNS LYMPHOMA: A Lymphoma Study
Association (LYSA) APROACH
F Morschhauser (Hematology, Lyon University, Lyon, France)
09:10 – 09:30
Long term remissions in patients with secondary cns lymphoma
A Korfel (Charité Berlin, Berlin, Germany)
09:30 – 09:50
The balance of benefit / tolerability in eradicating cns disease in
lymphoma
M Spina, (Division of Medical Oncology A, National Cancer Institute, Italy)
09:50 – 10:00
Questions
ehaweb.org
13
SATELLITE SYMPOSIUM SUPPORTED BY ARIAD
08:00 – 10:00, Hall: A9
CLINICAL OPTIONS AND CHALLENGES IN PH+ LEUKEMIA
FOLLOWING RESISTANCE OR INTOLERANCE TO INITIAL LINES
OF TYROSINE KINASE INHIBITORS
Chair: M Baccarani (Universitá di Bologna, Bologna, Italy)
08:00 – 08:10
Introduction and CML case study
M Baccarani (Universitá di Bologna, Bologna, Italy)
08:10 – 08:35
1G/2G TKIs in Ph+ CML
F Guilhot (Centre Hospitalier Universitaire, La Milétrie, in Poitiers, France)
08:35 – 09:00
1G/2G TKIs in Ph+ ALL
O Ottmann (Klinikum und Fachbereich Medizin, Johann Wolfgang GoetheUniversität, Frankfurt am Main, Germany)
09:00 – 09:25
How will we manage CML in the next 5 years?
S O’Brien (Northern Institute for Cancer Research, Newcastle University
Medical School, United Kingdom)
09:25 – 10:00
Discussion
All
14
SATELLITE SYMPOSIUM SPONSORED BY PRIME ONCOLOGY.
SUPPORTED BY CELGENE CORPORATION; MILLENNIUM, THE TAKEDA
ONCOLOGY COMPANY; MUNDIPHARMA INTERNATIONAL LIMITED; NOVARTIS
ONCOLOGY; ONYX PHARMACEUTICALS, INC.; AND TAKEDA.
10:45 – 12:45, Hall: A1
RELAPSED/REFRACTORY MULTIPLE MYELOMA:
THERAPEUTIC OPPORTUNITIES FOR ADVANCED DISEASE
Chair: U Mellqvist (Sahlgrenska University Hospital, Gothenburg, Sweden)
10:45 – 11:05
Defining relapsed/refractory multiple myeloma: Where the story begins
U Mellqvist (Sahlgrenska University Hospital, Gothenburg, Sweden)
11:05 – 11:30
Contemporary management of relapsed/refractory disease: Where are
we now?
P Moreau (Centre Hospitalier Universitaire, Hôtel-Dieu, Nantes, France)
11:30 – 12:00
Emerging agents and novel treatment strategies: Future therapeutic
options
J San Miguel (University of Salamanca, Salamanca, Spain)
12:00 – 12:25
Tailoring therapy for the elderly patient with relapsed/refractory
myeloma
M Dimopoulos (University of Athens, Athens, Greece)
12:25 – 12:40
Forecasting the future: A panel discussion
All Faculty
12:40 – 12:45
Closing comments
U Mellqvist (Sahlgrenska University Hospital, Gothenburg, Sweden)
ehaweb.org
15
SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS
10:45 – 12:45, Victoria Hall
ADVANCES IN THE MANAGEMENT OF CML: FROM
FRONTLINE THERAPY TO TREATMENT-FREE REMISSION
Chair: L Stenke (Karolinska University Hospital Stockholm, Sweden)
10:45 – 10:50
Welcome and introduction
L Stenke (Karolinska University Hospital Stockholm, Sweden)
10:50 – 11:05
Treatment milestones in CML: Evolution in action
M Baccarani (Institute of Hematology and Medical Oncology, ’Seragnoli
Bologna, Italy)
11:05 – 11:25
Early response: The hallmark of prognosis and use of second-generation
TKI in frontline CML therapy (a long-term view)
R Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom)
11:25 – 11:35 Questions and answers
11:35 – 11:50
Management of “less than optimal” response in 2013: New definitions,
new action
T Hughes (Centre for Cancer Biology, SA Pathology, Adelaide, Australia)
11:50 – 12:05
Molecular monitoring and impact of achieving deep molecular response
N Cross (Wessex Regional Genetics Laboratory Salisbury, United Kingdom)
12:15 – 12:30
Management of minimal residual disease and treatment-free remission
strategies
D Rea (Services des Maladies du Sang Hospital, Paris, France)
12:40 – 12:45
Conclusions and closing remarks
L Stenke (Karolinska University Hospital Stockholm, Sweden)
16
SATELLITE SYMPOSIUM SUPPORTED BY SANOFI
10:45 – 12:45, Hall: A2/A3
SELECTIVE JAK/STAT INHIBITION: SIGNALLING A WAY
FORWARD IN THE MANAGEMENT OF MYELOFIBROSIS
Chair: C Harrison (Guy's and St. Thomas' NHS Foundation Trust, London,
United Kingdom)
10:45 – 10:55
Introduction to current and future treatments of Myelofibrosis
C Harrison (Guy's and St. Thomas' NHS Foundation Trust, London, United
Kingdom)
10:55 – 11:15
Treatment of Myelofibrosis – what do new JAK2 inhibitors add to the
field?
Kingdom)
11:15 – 11:35
Selective JAK2 inhibitors targeting the JAK-STAT pathway in malignancy
R Skoda (University Hospital Basel, Basel, Switzerland)
11:35 – 11:55
Importance of the reversal of bone marrow fibrosis
NM Kröger (University Hospital Hamburg-Eppendorf, Hamburg, Germany)
11:55 – 12:15
How to overcome resistance to JAK2 inhibitors
JJ Kiladjian (Saint-Louis Hospital Paris, Paris, France)
12:15 – 12:35
Audience Q&A
12:35 – 12:45
Concluding remarks
Kingdom)
ehaweb.org
17
SATELLITE SYMPOSIUM SUPPORTED BY GLAXOSMITHKLINE
10:45 – 12:45, Hall: A4/A5
BEYOND PLATELET COUNTS: EXTENDING EXPERIENCE OF
MANAGING CHRONIC ADULT ITP
Co-Chairs: J Bussel (Weill Medical College of Cornell University, New York,
United States of America)
R Stasi (St George’s Hospital, London, United Kingdom)
10:45 – 10:50
Introduction and Welcome
J Bussel (Weill Medical College of Cornell University, New York, United States
of America)
10:50 – 11:05
ITP: is the latest clinical evidence reflected in clinical practice?
TPO-R agonists: an interactive session to address challenging questions
on the use of TPO-R agonists in adult chronic ITP
11:05 – 11:25
1. Understanding efficacy and administration
G Cheng (Chinese University of Hong Kong, Hong Kong, China)
11:25 – 11:45
2. Considering safety and tolerability
M Saleh (Georgia Cancer Specialists, Marietta, United States of America)
11:45 – 12:00
3. Examining the quality of life perspective when treating adult chronic ITP
H Frederiksen (Department of Haematology, Odense University Hospital,
Denmark)
12:00 – 12:25
How I treat adult chronic ITP: debating treatment choices
Panel discussion: all faculty
12:25 – 12:45
Questions and Answers
Close
18
SATELLITE SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB
10:45 – 12:45, Hall: K1/K2
PATIENT FOR DRUG OR DRUG FOR PATIENT? CHOOSING THE
BEST OPTION FOR THE INDIVIDUAL IN CP-CML
Chair: JL Steegmann (Hospital Universitario de la Princesa, Madrid, Spain)
Co-chair: J Richter (University Hospital of Lund, Sweden)
10:45 – 10:50
JL Steegmann (Hospital Universitario de la Princesa, Madrid, Spain)
10:50 – 11:15
Early and deep molecular response predictive of long term outcome in
CP-CML
G Rosti (S. Orsala-Malpighi Hospital, Bologna, Italy)
11:15 – 12:00
How to optimize switch to ensure optimal treatment in CP-CML? –
Patient cases perspective
Patient case 1: Treatment strategy for a patient taking imatinib 400mg
QD with no MR<10% at 3 months
E Olavarria (Hospital de Navarra, Pamplona, Spain)
Patient case 2: Treatment strategy for a patient with intolerance to
imatinib but in MMR
A Abbruzzese (Tor Vergata University, S. Eugenio Hospital, Rome, Italy)
Patient case 3: Treatment strategy for a patient without MMR but with
stable CCyR
12:00 – 12:25
Key clinical considerations for treatment success in CP-CML
E Jabbour (MDACC, Houston, USA)
12:25 – 12:40
Q&A and debate
12:40 – 12:45
Closing remarks
ehaweb.org
19
SATELLITE SYMPOSIUM SUPPORTED BY CELGENE
10:45 – 12:45, Hall: T1/T2
THE ROLE OF NOVEL THERAPIES IN IMPROVING RESPONSES
AND THERAPY DURATION IN CLL AND NHL
Co-Chairs: C Dearden (The Royal Marsden Hospital, London, United
Kingdom)
E Kimby (Karolinska Institute, Karolinska University Hospital,
Stockholm, Sweden)
10:45 – 10:55
Welcome & Introduction
E Kimby (Karolinska Institute, Karolinska University Hospital, Stockholm,
Sweden)
10:55 – 11:40
Debate: Is achieving MRD negativity key to sustained disease control?
The MCL experience
S Le Gouill (University Hospital of Nantes, Nantes, France)
C Pott (University Hospital Schleswig-Holstein, Kiel, Germany)
11:40 – 12:05
Disease control in CLL: what are the roles of immunomodulation,
signalling pathway inhibition and maintenance therapy?
M Hallek (University of Cologne, Cologne, Germany)
12:05 – 12:30
Can novel agents enhance maintenance therapy in NHL?
B Coiffier (Hospices Civils of Lyon, and Claude Bernard University, Lyon,
France)
12:30 – 12:45
Closing remarks
C Dearden (The Royal Marsden Hospital, London, United Kingdom)
20
10:45 – 12:45, Hall: C6/C7
DEFINING OPTIMAL COMBINATION STRATEGIES IN THE
MANAGEMENT OF FOLLICULAR AND MANTLE CELL LYMPHOMAS
Chair: F Morschhauser (Centre Hospitalier Universitaire de Lille, Lille, France)
10:45 – 10:55
Follicular and mantle cell lymphomas: The current treatment landscape
F Morschhauser (Centre Hospitalier Universitaire de Lille, Lille, France)
10:55 – 11:20
State of the art treatment for de novo follicular lymphoma
M Rummel (Hospital of the Justus-Liebig University, Giessen, Germany)
11:20 – 11:45
Follicular lymphoma: New options at relapse
F Offner (Ghent University, Ghent, Belgium)
11:45 – 12:10
Treatment options for MCL patients unfit for intensive therapy
C Visco (San Bortolo Hospital, Vicenza, Italy)
12:10 – 12:35
Current and new approaches for the younger MCL patient
S Le Gouill (Université de Nantes, Nantes, France)
12:35 – 12:45
Final questions and conclusions
F Morschhauser (Centre Hospitalier Universitaire de Lille, Lille, France)
ehaweb.org
21
13:30 – 15:30, Victoria Hall
NEXT STEPS FOR TARGETED THERAPY IN MPN
Chair: C Harrison (Guy’s and St Thomas Hospital London, United Kingdom)
13:30 – 13:35
C Harrison (Guy’s and St Thomas Hospital London, United Kingdom)
13:35 – 13:50
Central role of JAK2 signalling in MPN
N Cross (Wessex Regional Genetics Laboratory University of Southampton,
Salisbury, United Kingdom)
13:50 – 14:05
How important is the JAK2 V617F mutation in MPN?
A Vannucchi (University of Florence, Italy)
14:05 – 14:15
Questions and answers
14:15 – 14:30
Impact of ruxolitinib on overall survival: An update from the COMFORT
trials
F Passamonti (Ospedale di Circolo e Fondazione Macchi Varese, Italy)
14:30 – 14:45
Safety of novel therapies in MPN
14:45 – 14:55
14:55 – 15:15
Future direction of MPN therapies
S Constantinescu (Ludwig Institute for Cancer Research, Brussels, Belgium)
15:15 – 15:25
15:25 – 15:30
Meeting close
22
SATELLITE SYMPOSIUM SUPPORTED BY PFIZER
13:30 – 15:30, Hall: A2/A3
LATEST DEVELOPMENTS AND FUTURE STRATEGIES IN ADULT
LEUKEMIAS
Chair: H Hjorth-Hansen (Norwegian University of Science and Technology,
Trondheim, Norway)
13:30 – 13:40
H Hjorth-Hansen (Norwegian University of Science and Technology,
Trondheim, Norway)
13:40 – 14:05
Latest Developments in Adult AML
S Castaigne (Centre Hospitalier de Versailles – Hôpital Mignot, France)
14:05 – 14:30
Future Directions in Adult AML
G Martinelli (University of Bologna, Bologna, Italy)
14:30 – 14:55
Latest Developments in CML
J Apperley (Imperial College London, London, United Kingdom)
14:55 – 15:20
Future Directions in CML
P Rousselot (Centre Hospitalier de Versailles – Hôpital Mignot, France)
15:20 – 15:30
Conclusion
H Hjorth-Hansen (Norwegian University of Science and Technology,
Trondheim, Norway)
ehaweb.org
23
SATELLITE SYMPOSIUM SUPPORTED BY JANSSEN
13:30 – 15:30, Hall: A4/A5
CONFESSIONS OF A MYELOMA EXPERT
Chair: U Mellqvist
Co-Chair: J San Miguel
13:30 – 13:40
U Mellqvist (Sahlgren's University Hospital, Gothenburg, Sweden)
13:40 – 14:00
Essentials for monitoring in multiple myeloma
J Miguel (Hospital Clinico Universitario de Salamanca, Salamanca, Spain)
14:00 – 14:10
Consolidation and/or maintenance therapy –
practical considerations
- Transplant setting
- Non-transplant setting
M Boccadoro (University of Torino, Torino, Italy)
U Mellqvist (Sahlgren's University Hospital, Gothenburg, Sweden)
14:10 – 14:30
Top tips on using prognostic factors for guiding
treatment decisions
P Moreau (University Hospital of Nantes, France)
14:30 – 14:50
Tackling relapse and resistance in clinical practice
M Dimopoulos (University Athens School of Medicine, Athens, Greece)
14:50 – 15:30
Panel discussion:
Future management of multiple myeloma
All faculty
Closing remarks:
J Miguel (Hospital Clinico Universitario de Salamanca, Salamanca, Spain)
24
13:30 – 15:30, Hall: K1/K2
EVOLVING STRATEGIES TO MANAGE MDS AND AML IN THE
ELDERLY
Co-Chairs: G Mufti (King’s College Hospital, London, United Kingdom)
L Nilsson (University Hospital Lund, Sweden)
13:30 – 13:40
Introduction
G Mufti (King’s College Hospital, London, United Kingdom)
13:40 – 14:00
Lower-risk MDS with deletions in chromosome 5 – how complex can it be?
A Kulasekararaj (King’s College Hospital, London, United Kingdom)
14:00 – 14:20
The evidence-based treatment of lower-risk MDS del(5q)
A Giagounidis (Marien Hospital, Düsseldorf, Germany)
14:20 – 14:30
Interactive discussion
14:30 – 14:50
Five years after azacitidine approval: remaining challenges in
higher-risk MDS
T Prebet (Institut Paoli Calmettes, Marseille, France)
14:50 – 15:10
The Austrian Azacitidine Registry: how ‘real-world’ data contribute to the
understanding of the clinical picture in WHO-AML
L Pleyer (Paracelsus Medical University Hospital, Salzburg, Austria)
15:10 – 15:20
Interactive discussion
15:20 – 15:30
Closing remarks
G Mufti (King’s College Hospital, London, United Kingdom)
ehaweb.org
25
SATELLITE SYMPOSIUM SUPPORTED BY AMGEN
13:30 – 15:30, Hall: T1/T2
BREAKING BARRIERS WITH BIOLOGICS:
EXAMPLES IN ITP AND ALL
Chairs: H Wadenvik (University of Gothenburg, Gothenburg, Sweden)
13:30 – 13:35
13:35 – 14:00
Today: unmet needs and current challenges in ITP
B Godeau (Henri Mondor Hospital, Créteil, France)
14:00 – 14:25
Tomorrow: the future of TPO-receptor agonists in haematology
A Newland (Queen Mary’s School of Medicine and Dentistry, London, United
Kingdom)
14:25 – 14:30
Q&A
14:30 – 14:55
Addressing unmet needs in ALL management
R Bassan (Ospedale dell’Angelo, Mestre, Italy)
14:55 – 15:10
Confronting minimal residual disease in ALL – emerging evidence with
blinatumomab
N Gökbuget (Goethe University Hospital, Frankfurt, Germany)
15:10 – 15:25
Blinatumomab in adult patients with relapsed/refractory ALL
M Topp (University Hospital of Würzburg, Würzburg, Germany
15:25 – 15:30
Q&A and meeting close
26
SATELLITE SYMPOSIUM SUPPORTED BY
INVIVOSCRIBE TECHNOLOGIES
13:30 – 15:30, Hall: A7
THE EVOLUTION OF CLONALITY TESTING – NEXT
GENERATION SEQUENCING IN THE DIAGNOSIS AND
MONITORING OF HEMATOLOGIC MALIGNANCIES
Chair: J Miller (San Diego, CA, United States of America)
13:30 – 13:45
J Miller (San Diego, CA, United States of America)
13:45 – 14:10
The Past and Present of Clonality Testing in Hematologic Malignancies
P Piccaluga (Department of Experimental, Diagnostic, and Specialty
Medicine, Bologna University Medical School; Unit of Hematopathology,
S Orsola Malpighi Hospital, Bologna, Italy)
14:10 – 14:35
New Methods for Clonality Analysis in Hematologic Malignancies
K Kriese (Department of Pathology, Vivantes Klinikum Neukoelln, Berlin,
Germany)
14:35 – 15:00
Applications for Targeted Deep Sequencing in Clonality Analysis
M. Klass (San Diego, CA, United States of America)
15:00 – 15:10
Concluding Remarks
J Miller (San Diego, CA, United States of America)
15:10 – 15:30
Open Discussion and Questions
ehaweb.org
27
SATELLITE SYMPOSIUM SUPPORTED BY TEVA
13:30 – 15:30, Hall: A8
RAISING THE STANDARDS IN THE MANAGEMENT OF
HAEMATOLOGY PATIENTS
Chair: A. Osterborg, Sweden
13:30 – 13:35
13:35 - 14:00
Latest advances in the treatment of APL patients
Pierre Fenaux, France
14:00 - 14:25
Improve outcomes in patients treated for aggressive NHL
Jens Hasskarl, Germany
14:25 - 14:50
A clinical overview of biosimilar G-CSF in Stem Cell Mobilization
A Nagler, Israel
14:50 - 15:15
Supportive care in high risk haematological patients
H. Ludwig, Austria
15:15 - 15:30
Panel discussion and conclusion
28
SATELLITE SYMPOSIUM SUPPORTED BY F. HOFFMANN-LA ROCHE LTD
16:15 – 18:15, Hall: A1
INNOVATIONS IN ANTIBODY THERAPY FOR LYMPHOID MALIGNANCIES
Chair: M Björkholm (Karolinska University Hospital, Solna, Stockholm, Sweden)
16:15 – 16:25
Chair's welcome: 50 years in Oncology
M Björkholm (Karolinska University Hospital, Solna, Stockholm, Sweden)
16:25 – 16:40
New approaches to antibody delivery
M Rummel (Hospital of the Justus-Liebig University, Gießen, Germany)
N Crosbie (Plymouth Hospitals NHS Trust, Plymouth, United Kingdom)
16:40 – 16:55
Pharmacokinetic and clinical parameters in subcutaneous therapy
A Davies (Southampton General Hospital, Southampton, United Kingdom)
16:55 – 17:10
Implications of subcutaneous therapy for pharmacoeconomics,
healthcare providers and patients
J Vaz Pinto Neto (Cettro - Centro de Câncer de Brasília, Brasília, Brazil)
17:10 – 17:25
Panel discussion and Q&A All faculty
17:25 – 17:40
New options in antibody therapy
T Illidge (University of Manchester, Academic Health Sciences Centre,
Manchester, United kingdom)
17:40 – 17:55
Addressing unmet medical needs in chronic lymphocytic leukaemia
M Hallek (University of Cologne, Cologne, Germany)
17:55 – 18:10
Panel discussion and Q&A All faculty
18:10 – 18:15
Chair's close
M Björkholm (Karolinska University Hospital, Solna, Stockholm, Sweden)
ehaweb.org
29
SATELLITE SYMPOSIUM SUPPORTED BY GLAXOSMITHKLINE
16:15 – 18:15, Hall: A4/A5
NOVEL STRATEGIES FOR PREDICTING RESPONSE TO
TREATMENT IN REFRACTORY CLL
Chair: A Schuh (Oxford Cancer and Haematology Centre, Oxford University
Hospitals, United Kingdom)
16:15 – 16:25
A Schuh (Oxford Cancer and Haematology Centre, Oxford University
Hospitals,United Kingdom)
16:25 – 16:50
TP53 deletion/mutation analysis for predicting treatment response:
where do we stand?
T Zenz (Nationales Centrum für Tumorerkrankungen (NCT) / Deutsches
Krebsforschungszentrum (DKFZ) and Universitätsklinikum Heidelberg,
Heidelberg, Germany)
16:50 – 17:15
Transforming response prediction to chemoimmunotherapy in CLL using
whole genome technologies
17:15 – 17:40
NOTCH1 mutations in CLL: molecular pathogenesis and clinical
significance
D Rossi (Amedeo Avogadro University of Eastern Piedmont, Novara, Italy)
17:40 – 18:05
Case studies: lessons from the clinic
T Zenz (Nationales Centrum für Tumorerkrankungen (NCT) / Deutsches
Krebsforschungszentrum (DKFZ) and Universitätsklinikum Heidelberg,
Heidelberg, Germany)
Panel discussion and Q&A
All faculty
18:05 – 18:15
Closing remarks
30
16:15 – 18:15, Hall: K1/K2
CURRENT AND FUTURE THERAPEUTIC STRATEGIES FOR
MULTIPLE MYELOMA
Chair: J San Miguel (University Hospital of Salamanca, Salamanca, Spain)
16:15 – 16:20
Welcome and intro
J San Miguel (University Hospital of Salamanca, Salamanca, Spain)
16:20 – 16:45
The implications of clonal evolution on long-term treatment strategies
for multiple myeloma
G Morgan (Institute of Cancer Research, Sutton, and Royal Marsden NHS
Foundation Trust, London, United Kingdom)
16:45 – 17:10
The role of maintenance therapy for patients with newly diagnosed
multiple myeloma
S Zweegman (VU University Medical Center, Amsterdam, Netherlands)
17:10 – 17:35
Individualized treatment at first relapse – is it a one size fits all?
X Leleu (Claude Huriez Hospital, University Hospital of Lille, Lille, France)
17:35 – 18:10
New treatment options for patients with advanced RRMM who have
received novel agents
18:10 – 18:15
Close
ehaweb.org
31
16:15 – 18:15, Hall: T1/T2
WHERE ARE WE TODAY IN THE MANAGEMENT OF
TRANSFUSION- AND NON-TRANSFUSION-DEPENDENT
THALASSEMIA?
Chair: JB Porter (University College London, London, United Kingdom)
16:15 – 16:20
JB Porter (University College London, London, United Kingdom)
16:20 – 16:40
Are we recognizing the broad spectrum of thalassemia?
JB Porter (University College Hospital, London, United Kingdom)
16:40 – 17:00
Management of the non-transfusion-dependent thalassemia (NTDT)
patient
A Kattamis (University of Athens, Athens, Greece)
17:00 – 17:10
Questions and answers on NTDT
All
17:10 – 17:30
Translating thalassemia guidelines into clinical practice
PJ Ho (Royal Prince Alfred Hospital, Sydney, Australia)
17:30 - 17:50
Tackling cardiac iron in transfusion-dependent thalassemia (TDT)
Y Aydinok (Ege University Medical School, Izmir, Turkey)
17:50 – 18:00
Looking forward: where would we like to be in 5 years in our treatment
of TDT and NTDT?
JB Porter (University College London, London, United Kingdom)
18:00 – 18:10
Questions and answers on TDT
All
32
SATELLITE SYMPOSIUM SUPPORTED BY ALEXION
16:15 – 18:15, Hall: A7
ADVANCES IN THE MANAGEMENT OF COMPLEMENTMEDIATED THROMBOTIC MICROANGIOPATHIES
Chair: P Mannuccio Mannucci (Scientific Director, Ca‘ Granda Maggiore
Hospital Foundation, Milan, Italy)
16:15 – 16:30
Welcome and Introductions
P Mannuccio Mannucci (Scientific Director, Ca‘ Granda Maggiore Hospital
Foundation, Milan, Italy)
16:30 – 17:00
Pathophysiology of Complement-Mediated TMAs
S Meri (Haartman Institute, Department of Bacteriology and Immunology,
University of Helsinki, Finland)
17:00 – 17:30
Differential Diagnosis of Complement-Mediated TMAs
S Cataland (Department of Internal Medicine Division of Hematology, Ohio
State University Hospital, United States of America)
17:30 – 18:00
Clinical Management of aHUS – A Complement-Mediated TMA
F Fakhouri (Department of Nephrology and UMR S-1064 University Hospital
of Nantes, France)
18:00 – 18:15
Questions and Answers
P Mannuccio Mannucci (Scientific Director, Ca‘ Granda Maggiore Hospital
Foundation, Milan, Italy)
ehaweb.org
33
SATELLITE SYMPOSIUM SUPPORTED BY VIFOR PHARMA
16:15 – 18:15, Hall: A8
MASTER CLASS ON IRON METABOLISM AND IV IRON
Chair: Y Beguin (Centre hospitalier universitaire de Liège, Liège, Belgium)
I. EXPOSITION
16:15 – 16:25
Setting the Stage: Welcome and Introduction
Y Beguin (Centre hospitalier universitaire de Liège, Liège, Belgium)
16:25 – 16:50
Describing the Physiology of iron and pathophysiology of iron deficiency
LT Goodnough (Stanford University Medical Center, Stanford CA, United
States of America)
II. CONFRONTATION
16:50 – 17:55
The Actors: Profile of I.V. irons
T Macdougall (King's College Hospital NHS Foundation Trust, London, United
Kingdom)
LT Goodnough (Stanford University Medical Center, Stanford CA, United
States of America)
III. SOLUTION
17:50 – 18:05
Setting up the Master Piece: Practical guidance on diagnosis and
treatment
Y Beguin (Centre hospitalier universitaire de Liège, Liège, Belgium)
18:05 – 18:15
All faculty
34
SATELLITE SYMPOSIUM SUPPORTED BY GENZYME
16:15 – 18:15, Hall: A9
THE SHERLOCK HOLMES APPROACH TO DIAGNOSIS AND
TREATMENT
Theme: White blood cell changes in rare haematological diseases
Chair: M Machaczka (Karolinska University Hospital Huddinge, Stockholm,
Sweden)
16:15 – 16:25
Introduction
M Machaczka (Karolinska University Hospital Huddinge, Stockholm, Sweden)
16:25 – 16:40
A sleepy suspect takes a turn for the worse
M Cappellini (“Ca Granda” Policlinico Foundation IRCCS, Milan University,
Milan, Italy)
16:40 – 16:55
The case of a curiously combustible conspirator
H Rosenbaum (Ramban Medical Centre and Bruce Rappaport Faculty of
Medicine, Haifa, Israel)
16:55 – 17:10
A conundrum of accomplices in crime
F Bauduer (Centre Hospitalier de la Côte Basque, Bayonne, France)
17:10 – 17:25
Young offenders make trouble for Holmes
M Cappellini (“Ca Granda” Policlinico Foundation IRCCS, Milan University, Italy)
17:25 – 17:40
A triad of clues gives Holmes a hint
H Rosenbaum (Ramban Medical Centre and Bruce Rappaport Faculty of
Medicine, Haifa, Israel)
17:40 – 17:55
Holmes has a hairy time!
F Bauduer (Centre Hospitalier de la Côte Basque, Bayonne, France)
17:55 – 18:15
Questions, summary and conclusions
M Machaczka (Karolinska University Hospital Huddinge, Stockholm, Sweden)
ehaweb.org
35
CORPORATE SPONSORS 2013
Platinum
Gold
Silver
Bronze
Contributors
36

Clinical Options and Challenges in Ph+ Leukemia

Transcription

Similar documents

Instrumental cables

ÖLfLEx® iNStrum SWA 280 h